BIOAGE LABS, INC. Operating Income
BIOAGE LABS, INC. (BIOA) reported Operating Income of -$29.33 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-05
- BIOAGE LABS, INC. operating income (loss) for the quarter ending 2026-06-30 was -$29.33M.
- BIOAGE LABS, INC. operating income (loss) for the quarter ending 2026-03-31 was -$25.38M.
- BIOAGE LABS, INC. operating income (loss) for the quarter ending 2025-12-31 was -$28.42M.
- BIOAGE LABS, INC. operating income (loss) for the quarter ending 2025-09-30 was -$23.14M.
- BIOAGE LABS, INC. operating income (loss) for fiscal 2025 was -$92.78M.
- BIOAGE LABS, INC. operating income (loss) for fiscal 2024 was -$78.19M.
- BIOAGE LABS, INC. operating income (loss) for fiscal 2023 was -$48.40M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$29.33M 10-Q · filed 2026-08-05 | -$54.71M 10-Q · filed 2026-08-05 | -$83.13M derived: sum of 3 quarters · filed 2026-08-05 | -$106.27M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$25.38M 10-Q · filed 2026-05-08 | -$53.80M derived: sum of 2 quarters · filed 2026-05-08 | -$76.94M derived: sum of 3 quarters · filed 2026-05-08 | -$101.71M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$28.42M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | -$51.56M derived: sum of 2 quarters · filed 2026-03-24 | -$76.33M derived: sum of 3 quarters · filed 2026-08-05 | -$92.78M 10-K · filed 2026-03-24 |
| 2025-09-30 | -$23.14M 10-Q · filed 2025-11-06 | -$47.91M derived: sum of 2 quarters · filed 2026-08-05 | -$64.36M 10-Q · filed 2025-11-06 | -$89.72M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$24.77M 10-Q · filed 2026-08-05 | -$41.22M 10-Q · filed 2026-08-05 | -$66.58M derived: sum of 3 quarters · filed 2026-08-05 | -$91.33M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$16.45M 10-Q · filed 2026-05-08 | -$41.81M derived: sum of 2 quarters · filed 2026-05-08 | -$66.56M derived: sum of 3 quarters · filed 2026-05-08 | -$81.83M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | -$25.36M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | -$50.11M derived: sum of 2 quarters · filed 2026-03-24 | -$65.38M derived: sum of 3 quarters · filed 2026-03-24 | -$78.19M 10-K · filed 2026-03-24 |
| 2024-09-30 | -$24.75M 10-Q · filed 2025-11-06 | -$40.02M derived: sum of 2 quarters · filed 2025-11-06 | -$52.83M 10-Q · filed 2025-11-06 | -$66.43M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$15.27M 10-Q · filed 2025-08-06 | -$28.08M 10-Q · filed 2025-08-06 | -$41.68M derived: sum of 3 quarters · filed 2025-08-06 | -$51.56M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | -$12.81M 10-Q · filed 2025-05-06 | -$26.41M derived: sum of 2 quarters · filed 2025-05-06 | -$36.30M derived: sum of 3 quarters · filed 2025-05-06 | |
| 2023-12-31 | -$13.60M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | -$23.48M derived: sum of 2 quarters · filed 2025-03-20 | -$48.40M 10-K · filed 2025-03-20 | |
| 2023-09-30 | -$9.89M 10-Q · filed 2024-11-07 | -$34.80M 10-Q · filed 2024-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |